Generated by AI
Voyager Therapeutics, Inc. is a biotechnology company focused on developing gene therapies and other genetic medicines for severe neurological diseases. The company’s current programs center on disorders such as Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s disease, and frontotemporal dementia. Its pipeline includes tau-focused and other neuroscience candidates, while its TRACER platform is designed to support adeno-associated virus-based delivery for targeted therapies. Voyager Therapeutics works at the intersection of genetics, neurology, and drug delivery, aiming to create treatments that address conditions with limited therapeutic options. Founded in 2013 and headquartered in Lexington, Massachusetts, the company plays a specialized role in the biotechnology market through its focus on neurogenetic research and clinical-stage development.
Website75 Hayden Avenue
Lexington, MA, 02421
United States
The latest articles about VYGR.
Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.
Summary of Mar 10's posts. Generated by AI.
Summary of Feb 29's posts. Generated by AI.
Summary of Oct 7's posts. Generated by AI.
Summary of Mar 10's posts. Generated by AI.
Investors talking about VYGR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.